Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 12/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.44 |
| ▸ | DRD3 | P35462 | 3/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6215791 | 0.90 | DRD2 (0.58) | DRD2ADRA1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL7234672 | 0.90 | DRD2 (0.59) | DRD2ADRA1ASIGMAR1ADRA1DADRA1B | |
| SCHEMBL7681348 | 0.82 | DRD2 (0.51) | DRD2ADRA1ASIGMAR1 | |
| SCHEMBL6969864 | 0.81 | HTR7 (0.40) | DRD2ADRA1ASIGMAR1DRD3 | |
| SCHEMBL6969857 | 0.80 | DRD3 (0.43) | ADRA1ASIGMAR1DRD3 | |
| SCHEMBL7566269 | 0.77 | DRD2 (0.63) | DRD2ADRA1ASIGMAR1ADRA1DADRA1B | |
| SCHEMBL6216974 | 0.76 | DRD2 (0.57) | DRD2ADRA1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL6197779 | 0.76 | DRD2 (0.55) | DRD2ADRA1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL7524346 | 0.76 | ADRA1A (0.57) | DRD2ADRA1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL6198575 | 0.76 | DRD2 (0.55) | DRD2ADRA1ASIGMAR1ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6620815-B1 | Selective antagonists for human alpha 1A receptors; benign prostatic hyperplasia, impotency, cardiac arrhythmia treatment; anticholesterol agents; intraocular pressure reduction | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-09-16 | — | — | US | disclosed |
| EP-0988295-A4 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 2003-08-13 | — | — | EP | disclosed |
| US-6159990-A | Oxazolidinones as α1A receptor antagonists | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
| EP-0988295-A1 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998057940-A1 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-12-23 | — | — | WO | disclosed |